Last reviewed · How we verify
Attenuated alive HAV vaccine
Attenuated alive HAV vaccine works by exposing the body to a weakened form of the hepatitis A virus, prompting an immune response without causing the disease.
Attenuated alive HAV vaccine works by exposing the body to a weakened form of the hepatitis A virus, prompting an immune response without causing the disease. Used for Prevention of hepatitis A.
At a glance
| Generic name | Attenuated alive HAV vaccine |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This immune response helps the body develop antibodies to fight the virus, providing long-term protection against hepatitis A infection. The vaccine is made from inactivated hepatitis A virus, which is grown in cell cultures and then inactivated with chemicals or heat. This process makes the virus unable to cause disease but still stimulates an immune response.
Approved indications
- Prevention of hepatitis A
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |